معرفی
Shayan Aryannezhad is a Clinical Research Fellow at the Nuffield Department of Population Health, University of Oxford, working on the ASCEND-PLUS trial investigating oral semaglutide therapy for type 2 diabetes since January 2025. He simultaneously completes his PhD at the MRC Epidemiology Unit, University of Cambridge, focusing on cardiometabolic disease epidemiology.
His educational background includes:
- Doctor of Medicine (MD) from Tehran, Iran (2021)
- Master of Public Health (MPH) from Tehran, Iran (2021)
Research interests center on epidemiological analysis of diet-physical activity interactions and longitudinal trajectories in cardiometabolic diseases, obesity, and bariatric surgery outcomes. His methodology emphasizes population-based prospective cohorts like EPIC-Norfolk and Fenland Study, examining how lifestyle factor changes influence diabetes incidence, cardiovascular events, mortality, and adiposity metrics through advanced longitudinal modeling.
Publication trends (2022-2025) reveal consistent focus on multi-factorial lifestyle interventions, with 4 of 5 recent works analyzing physical activity-diet synergies in mortality and diabetes prevention using UK-based cohorts. His research bridges clinical trial work (ASCEND-PLUS) with observational epidemiology, highlighting translational pathways from lifestyle patterns to hard clinical endpoints.
No scientific awards are documented in current records.
Active involvement spans clinical trial coordination (ASCEND-PLUS), PhD research at Cambridge, and contributions to major cohort studies. His work demonstrates strong grant-supported infrastructure through MRC Epidemiology Unit and NDPH resources, with future directions likely emphasizing pharmacological-lifestyle interaction trials in diabetes management.
